Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL, van Lohuizen M, Gargiulo G.

J Exp Med. 2018 Dec 3;215(12):3115-3135. doi: 10.1084/jem.20180801. Epub 2018 Nov 28.

2.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Šuštić T, van Wageningen S, Bosdriesz E, Reid RJD, Dittmar J, Lieftink C, Beijersbergen RL, Wessels LFA, Rothstein R, Bernards R.

Genome Med. 2018 Nov 27;10(1):90. doi: 10.1186/s13073-018-0600-z.

3.

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R.

J Hepatol. 2018 Nov;69(5):1057-1065. doi: 10.1016/j.jhep.2018.07.004. Epub 2018 Jul 18.

PMID:
30030148
4.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK.

Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082.

5.

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

Jastrzebski K, Thijssen B, Kluin RJC, de Lint K, Majewski IJ, Beijersbergen RL, Wessels LFA.

Cancer Res. 2018 Aug 1;78(15):4396-4410. doi: 10.1158/0008-5472.CAN-17-2698. Epub 2018 May 29.

PMID:
29844118
6.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 Aug;37(33):4611-4625. doi: 10.1038/s41388-018-0300-6. Epub 2018 May 15.

7.

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R.

Cell Res. 2018 Jun;28(6):690-692. doi: 10.1038/s41422-018-0020-z. Epub 2018 Mar 5. No abstract available.

PMID:
29507396
8.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R.

Mol Cancer Ther. 2018 Apr;17(4):849-857. doi: 10.1158/1535-7163.MCT-17-0868. Epub 2018 Feb 13.

PMID:
29440296
9.

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, Lieftink C, Morris B, Jochems F, Willemsen L, Beijersbergen RL, Bernards R.

Cell Rep. 2017 Oct 17;21(3):773-783. doi: 10.1016/j.celrep.2017.09.085.

10.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.

Eur Urol. 2017 Jun;71(6):858-862. doi: 10.1016/j.eururo.2017.01.021. Epub 2017 Jan 17.

PMID:
28108151
11.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.

12.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.

13.

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

Miles DC, de Vries NA, Gisler S, Lieftink C, Akhtar W, Gogola E, Pawlitzky I, Hulsman D, Tanger E, Koppens M, Beijersbergen RL, van Lohuizen M.

Stem Cells. 2017 Jan;35(1):147-157. doi: 10.1002/stem.2453. Epub 2016 Jul 6.

14.

Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform.

Jastrzebski K, Evers B, Beijersbergen RL.

Methods Mol Biol. 2016;1470:49-73. doi: 10.1007/978-1-4939-6337-9_5.

PMID:
27581284
15.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS.

Oncotarget. 2016 Jul 12;7(28):42859-42872. doi: 10.18632/oncotarget.10230.

16.

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

de Lint K, Poell JB, Soueidan H, Jastrzebski K, Vidal Rodriguez J, Lieftink C, Wessels LF, Beijersbergen RL.

Mol Cancer Ther. 2016 Jul;15(7):1545-56. doi: 10.1158/1535-7163.MCT-15-0865. Epub 2016 May 11.

17.

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R.

Nat Biotechnol. 2016 Jun;34(6):631-3. doi: 10.1038/nbt.3536. Epub 2016 Apr 25.

PMID:
27111720
18.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.

19.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R.

Cell Rep. 2015 Sep 29;12(12):1978-85. doi: 10.1016/j.celrep.2015.08.037. Epub 2015 Sep 10.

20.

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.

Barrangou R, Birmingham A, Wiemann S, Beijersbergen RL, Hornung V, Smith Av.

Nucleic Acids Res. 2015 Apr 20;43(7):3407-19. doi: 10.1093/nar/gkv226. Epub 2015 Mar 23. Review.

21.

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

Papadakis AI, Sun C, Knijnenburg TA, Xue Y, Grernrum W, Hölzel M, Nijkamp W, Wessels LF, Beijersbergen RL, Bernards R, Huang S.

Cell Res. 2015 Apr;25(4):445-58. doi: 10.1038/cr.2015.16. Epub 2015 Feb 6.

22.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS.

Cell Rep. 2014 Nov 20;9(4):1375-86. doi: 10.1016/j.celrep.2014.10.024. Epub 2014 Nov 6.

23.

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

Drosten M, Sum EY, Lechuga CG, Simón-Carrasco L, Jacob HK, García-Medina R, Huang S, Beijersbergen RL, Bernards R, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15155-60. doi: 10.1073/pnas.1417549111. Epub 2014 Oct 6.

24.

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

Evers B, Bernards R, Beijersbergen RL.

Mol Syst Biol. 2014 Jul 1;10:738. doi: 10.15252/msb.20145372. No abstract available.

25.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

26.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R.

Cell Rep. 2014 Apr 10;7(1):86-93. doi: 10.1016/j.celrep.2014.02.045. Epub 2014 Mar 27.

27.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

28.

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

Bajpe PK, Heynen GJ, Mittempergher L, Grernrum W, de Rink IA, Nijkamp W, Beijersbergen RL, Bernards R, Huang S.

Mol Cell Biol. 2013 Aug;33(16):3343-53. doi: 10.1128/MCB.01213-12. Epub 2013 Jun 17.

29.

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R.

Cell. 2012 Nov 21;151(5):937-50. doi: 10.1016/j.cell.2012.10.035.

30.

Functional subtyping of breast cancer.

Beijersbergen RL, Bernards R.

Cancer Discov. 2011 Aug;1(3):205-6. doi: 10.1158/2159-8290.CD-11-0163.

31.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R.

Nature. 2012 Jan 26;483(7387):100-3. doi: 10.1038/nature10868.

32.

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

Kuiken HJ, Egan DA, Laman H, Bernards R, Beijersbergen RL, Dirac AM.

J Cell Mol Med. 2012 Sep;16(9):2140-9. doi: 10.1111/j.1582-4934.2012.01524.x.

33.

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

Nijwening JH, Geutjes EJ, Bernards R, Beijersbergen RL.

PLoS One. 2011;6(9):e25235. doi: 10.1371/journal.pone.0025235. Epub 2011 Sep 27.

34.

A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation.

Paul P, van den Hoorn T, Jongsma ML, Bakker MJ, Hengeveld R, Janssen L, Cresswell P, Egan DA, van Ham M, Ten Brinke A, Ovaa H, Beijersbergen RL, Kuijl C, Neefjes J.

Cell. 2011 Apr 15;145(2):268-83. doi: 10.1016/j.cell.2011.03.023. Epub 2011 Mar 31.

35.

Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.

Nijwening JH, Kuiken HJ, Beijersbergen RL.

Cell Cycle. 2011 Feb 1;10(3):380-6. Epub 2011 Feb 1.

PMID:
21239890
36.

Exploration of synthetic lethal interactions as cancer drug targets.

Kuiken HJ, Beijersbergen RL.

Future Oncol. 2010 Nov;6(11):1789-802. doi: 10.2217/fon.10.131. Review.

PMID:
21142664
37.

Using large-scale RNAi screens to identify novel drug targets for cancer.

Nijwening JH, Beijersbergen RL.

IDrugs. 2010 Nov;13(11):772-7. Review.

PMID:
21046524
38.

Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.

Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA.

Oncogene. 2010 Nov 11;29(45):6071-83. doi: 10.1038/onc.2010.333. Epub 2010 Aug 16.

PMID:
20711236
39.

Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade.

Mullenders J, Fabius AW, van Dongen MM, Kuiken HJ, Beijersbergen RL, Bernards R.

Mol Cancer Res. 2010 Apr;8(4):592-603. doi: 10.1158/1541-7786.MCR-09-0386. Epub 2010 Mar 23.

40.

Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.

Mullenders J, von der Saal W, van Dongen MM, Reiff U, van Willigen R, Beijersbergen RL, Tiefenthaler G, Klein C, Bernards R.

Clin Cancer Res. 2009 Sep 15;15(18):5811-9. doi: 10.1158/1078-0432.CCR-09-0261. Epub 2009 Sep 1.

41.

Statistical methods for analysis of high-throughput RNA interference screens.

Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE.

Nat Methods. 2009 Aug;6(8):569-75. doi: 10.1038/nmeth.1351. Review.

42.

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R.

Cancer Cell. 2009 Apr 7;15(4):328-40. doi: 10.1016/j.ccr.2009.02.023.

43.

A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.

Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL.

PLoS One. 2009;4(3):e4798. doi: 10.1371/journal.pone.0004798. Epub 2009 Mar 11.

44.

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J.

Cancer Res. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740.

45.

Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1.

Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den Nieuwendijk R, van den Eeden SJ, Geluk A, Poot A, van der Marel G, Beijersbergen RL, Overkleeft H, Ottenhoff TH, Neefjes J.

Nature. 2007 Nov 29;450(7170):725-30.

PMID:
18046412
46.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.

47.

shRNA libraries and their use in cancer genetics.

Bernards R, Brummelkamp TR, Beijersbergen RL.

Nat Methods. 2006 Sep;3(9):701-6. Review.

PMID:
16929315
48.

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL.

Nat Chem Biol. 2006 Apr;2(4):202-6. Epub 2006 Feb 13.

PMID:
16474381
49.

Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells.

Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC.

Mol Cell. 2005 Dec 9;20(5):673-85.

50.

Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.

Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL.

Cold Spring Harb Symp Quant Biol. 2004;69:439-45. No abstract available.

PMID:
16117679

Supplemental Content

Loading ...
Support Center